Activating the tumor-associated immune system with an siRNA conjugated to a Toll-like receptor 9 ligand is a promising anticancer strategy.
References
Aouadi, M. et al. Nature 458, 1180–1184 (2009).
MacDiarmid, J.A. et al. Nat. Biotechnol. 27, 643–651 (2009).
Peer, D. et al. Science 319, 627–630 (2008).
Poeck, H. et al. Nat. Med. 14, 1256–1263 (2008).
Sato, Y. et al. Nat. Biotechnol. 26, 431–442 (2008).
Kortylewski, M. et al. Nat. Biotechnol. 27, 925–932 (2009).
Marques, J.T. & Williams, B.R. Nat. Biotechnol. 23, 1399–1405 (2005).
Kleinman, M.E. et al. Nature 452, 591–597 (2008).
Kortylewski, M. et al. Nat. Med. 11, 1314–1321 (2005).
McNamara, J.O. II et al. Nat. Biotechnol. 24, 1005–1015 (2006).
MacDiarmid, J.A. et al. Cancer Cell 11, 431–445 (2007).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gantier, M., Williams, B. siRNA delivery not Toll-free. Nat Biotechnol 27, 911–912 (2009). https://doi.org/10.1038/nbt1009-911
Issue Date:
DOI: https://doi.org/10.1038/nbt1009-911
- Springer Nature America, Inc.
This article is cited by
-
Rational Design of Immunostimulatory siRNAs
Molecular Therapy (2010)